Innovative Molecules, a German, Munich-based drug development company focused on developing next-generation treatments for Herpes simplex-induced diseases, has closed a EUR20 million Series A equity financing round led by LSP (Life Sciences Partners).
The company will use the funds to advance its preclinical product candidate, IM-250, from the current late preclinical stage to a Phase 2 proof-of-concept study.
IM-250 is a potent inhibitor of Herpes Simplex Virus type 1 (HSV-1) and type 2 (HSV-2) replication. The compound targets the helicase-primase enzyme complex of the virus. Due to its demonstrated impact on the viral reservoir in preclinical studies, IM-250 may become a game-changer for the treatment of HSV-related diseases due to its potential to alter the natural course of the disease.
Gerald Kleymann, founder & Chief Executive Officer at Innovative Molecules, says: “Within the last 25 years the treatment of Herpes simplex has not seen an innovation that managed to reach the market. Our ambition is to change this. With IM-250 we will alter the way Herpes is treated. Our goal is to reduce or even eradicate the reservoir of the virus in order to achieve long-lasting effects, less recurrences and real benefits for patients.“
Read more/Source: Private Equity Wire
